Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy of early intervention with Memantine and Pioglitazone in preventing Radiation-Induced Brain Injury (RIBI) in patients undergoing cranial radiotherapy.
RIBI, a significant complication of radiation therapy for primary and metastatic brain tumors, as well as head and neck cancers, often presents with delayed and irreversible neurological damage, severely affecting patients' quality of life.
Our previous studies have indicated that Memantine, an NMDAR antagonist, and Pioglitazone, a PPAR-γ agonist, play crucial roles in modulating the neuroprotective immune microenvironment by targeting key mechanisms of neuron-astrocyte fatty acid metabolism coupling. These findings suggest that early administration of these drugs could protect cognitive function and reduce neuroinflammation in patients post-radiation.
This prospective phase II clinical trial will assess the combined efficacy of Memantine and Pioglitazone in improving cognitive outcomes and preventing RIBI without adversely impacting the anti-tumor efficacy of radiation therapy. The study will also explore the synergistic effects of these two FDA-approved drugs in early-stage RIBI prevention, providing a new therapeutic strategy for enhancing the quality of life in cancer patients receiving radiotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborators:
Fujian Medical University Union Hospital Guangdong Provincial People's Hospital Southern Medical University, China The Affiliated Panyu Center Hospital of Guangzhou Medical University The Central Hospital of Shaoyang City